NMR-based metabonomics of cerebrospinal fluid applied to amyotrophic lateral sclerosis

Biocybernetics and Biomedical Engineering

Volumn 33, Issue 1, 2013, Pages 21-32

  Toczyłowska, Beata ^a,b   Jamrozik, Zygmunt ^c   Liebert, Adam ^a   Kwiecinski, Hubert ^c  

^a INSTITUTE OF BIOCYBERNETICS AND BIOMEDICAL ENGINEERING   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Amyotrophic lateral sclerosis; Cerebrospinal fluid; Discriminant analysis; Metabolomics; NMR spectroscopy

Indexed keywords

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANAEROBIC METABOLISM; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; EXCITOTOXICITY; FEMALE; HUMAN; MALE; METABOLITE; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 84880521816     PISSN: 02085216     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0208-5216(13)70053-6     Document Type: Article

References (40)

1. Cleveland D.W., Rothstein J.D.: From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci 2001, 2, 806-819.
2. Beuche W., Yushchenko M., Mader M., Maliszewska M., Felgenhauer K., Weber F.: Matrix metalloproteinase- 9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport 2000, 11, 3419-3422.
3. Bogdanov M., Brown R.H., Matson W., Smart R., Hayden D., O'Donnell H., Flint B.M., Cudkowicz M.: Increased oxidative damage to DNA in ALS patients. Free Radic. Biol. Med. 2000, 29, 652-658.
4. Camu W., Billiard M., Baldy-Moulinier M.: Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol. Scand. 1993, 88, 51-55.
5. Rozen S., Cudkowicz M.E., Bogdanov M., Matson W.R., Kristal B.S., Beecher C., Harrison S., Vouros P., Flarakos J., Vigneau-Callahan K., Matson T.D., Newhall K.M., Beal M.F., Brown R.H., Kaddurah-Daouk R.: Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005, 1, 101-108.
6. Mitchell R.M., Simmons Z., Beard J.L., Stephens H.E., Connor J.R.: Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve 2010, 42, 95-103.
7. Wilson M.E., Boumaza I., Lacomis D., Bowser R., Cystatin C.: A candidate biomarker for amyotrophic lateral sclerosis. PLoS One 2010, 5, e15133.
8. Holmes E., Tsang T.M., Tabrizi S.J.: The application of NMR-based metabonomics in neurological disorders. NeuroRx 2006, 3, 358-372.
9. Viant M.R., Lyeth B.G., Miller M.G., Berman R.F.: An NMR metabolomic investigation of early metabolic disturbances following traumatic brain injury in a mammalian model. NMR Biomed. 2005, 18, 507-516.
10. Holmes E., Tsang T.M., Huang J.T., Leweke F.M., Koethe D., Gerth C.W., Nolden B.M., Gross S., Schreiber D., Nicholson J.K., Bahn S.: Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006, 3, e327.
11. Toczyłowska B., Chalimoniuk M., Wodowska M., Mayzner-Zawadzka E.: Changes in concentration of cerebrospinal fluid components in patients with traumatic brain injury. Brain Res. 2006, 1104, 183-189.
12. Bowser R., Lacomis D.: Applying proteomics to the diagnosis and treatment of ALS and related diseases. Muscle Nerve 2009, 40, 753-762.
13. Pal K., Sharma U., Gupta D.K., Pratap A., Jagannathan N.R.: Metabolite profile of cerebrospinal fluid in patients with spina bifida: a proton magnetic resonance spectroscopy study. Spine (Phila Pa 1976 ) 2005, 30, E68-E72.
14. Brooks B.R., Miller R.G., Swash M., Munsat T.L.: El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral. Scler. Other Motor Neuron Disord 2000, 1, 293-299.
15. Wevers R.A., Engelke U., Wendel U., de Jong J.G., Gabreels F.J., Heerschap A.: Standardized method for high-resolution 1H-NMR of cerebrospinal fluid. Clin. Chem. 1995, 41, 744-751.
16. Lutz N.W., Maillet S., Nicoli F., Viout P., Cozzone P.J.: Further assignment of resonances in 1H NMR spectra of cerebrospinal fluid (CSF). FEBS Lett. 1998, 425, 345-351.
17. Kriat M., Nicoli F., Vion-Dury J., Confort-Gouny S., Dano P., Grisoli F., Gastaut J.L., Cozzone P.J.: High resolution NMR spectroscopy of CSF: methodological issues and perspective clinical applications. Ann. Biol. Clin. (Paris) 1991, 49, 461-467.
18. van den Berg R.A., Hoefsloot H.C., Westerhuis J.A., Smilde A.K., van der Werf M.J.: Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 2006, 7, 142.
19. Karp N.A., Griffin J.L., Lilley K.S.: Application of partial least squares discriminant analysis to two-dimensional difference gel studies in expression proteomics. Proteomics 2005, 5, 81-90.
20. Li X., Yang S.B., Qiu Y.P., Zhao T., Chen T.L., Su M.M., Chu L.X., Lv A.P., Liu P., Jia W.: Urinary metabolomics as a potentially novel diagnostic and stratification tool for knee osteoarthritis. Metabolomics 2010, 6, 109-118.
21. Trygg J., Wold S.: Orthogonal projections to latent structures (O-PLS). Journal of Chemometrics 2002, 16, 19-128.
22. Wold S., Antti H., Lindgren F., Ohman J.: Orthogonal signal correction of near-infrared spectra. Chemometrics and Intelligent Laboratory Systems 1998, 44, 175-185.
23. Westerhuis J.A., de Jong S., Smilde A.K.: Direct orthogonal signal correction. Chemometrics and Intelligent Laboratory Systems 2001, 56, 13-25.
24. Bylesjo M., Rantalainen M., Cloarec O., Nicholson J.K., Holmes E., Trygg J.: OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. Journal of Chemometrics 2006, 20, 341-351.
25. Ellis D.I., Dunn W.B., Griffin J.L., Allwood J.W., Goodacre R.: Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 2007, 8, 1243-1266.
26. Lajtha A., Gibson G.E., Daniels G.A.: Brain energetics. Integration of molecular and cellular processes. Springer 2007.
27. Irani D.N.: Cerebrspinal fluid in clinical practice. Springer Inc. 2009.
28. Vijayalakshmi K., Alladi P.A., Sathyaprabha T.N., Subramaniam J.R., Nalini A., Raju T.R.:Cerebrospinal fluid from sporadic amyotrophic lateral sclerosis patients induces degeneration of a cultured motor neuron cell line. Brain Res. 2009, 1263, 122-133.
29. Blasco H., Corcia P., Moreau C., Veau S., Fournier C., Vourc'h P., Emond P., Gordon P., Pradat P.F., Praline J., Devos D., Nadal-Desbarats L., Andres C.R.: 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS One 2010, 5, e13223.
30. Kumar A., Bala L., Kalita J., Misra U.K., Singh R.L., Khetrapal C.L., Babu G.N.: Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clin. Chim. Acta 2010, 411, 563-567.
31. Siegel G.J., Albers W.: Basic neurochemistry: molecular, cellular, and medical aspects. Tom 1. Elsevier Academic Press, 2006.
32. Elble R., Giacobini E., Higgins C.: Choline levels are increased in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging 1989, 10, 45-50.
33. Zwingmann C., Richter-Landsberg C., Brand A., Leibfritz D.: NMR spectroscopic study on the metabolic fate of [3-(13)C]alanine in astrocytes, neurons, and cocultures: implications for glia-neuron interactions in neurotransmitter metabolism. Glia 2000, 32, 286-303.
34. Lederer C.W., Torrisi A., Pantelidou M., Santama N., Cavallaro S.: Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics 2007, 8, 26.
35. Globus M.Y., Ginsberg M.D., Busto R.: Excitotoxic index - A biochemical marker of selective vulnerability. Neurosci Lett. 1991, 127, 39-42.
36. Niebroj-Dobosz I., Janik P.: Amino acids acting as transmitters in amyotrophic lateral sclerosis (ALS). Acta Neurol. Scand. 1999, 100, 6-11.
37. Niebroj-Dobosz I., Janik P., Mickielewicz A., Jamrozik Z., Kwiecinski H.: Neurotoxic activity of serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients against some enzymes of glutamate metabolism. Neurol. Neurochir. Pol. 2001, 35, 81-89.
38. Shi P., Wei Y., Zhang J., Gal J., Zhu H.: Mitochondrial dysfunction is a converging point of multiple pathological pathways in amyotrophic lateral sclerosis. J. Alzheimers Dis. 2010, 20 Suppl 2, S311-S324.
39. Kuwabara S.: Amyotrophic lateral sclerosis - electrophysiologic aspects of its pathophysiology and new therapeutic options. Brain Nerve 2010, 62, 885-891.
40. Shaw P.J., Forrest V., Ince P.G., Richardson J.P., Wastell H.J.: CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995, 4, 209-216.